Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
111 results about "Hypertrophic scar" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A hypertrophic scar is a cutaneous condition characterized by deposits of excessive amounts of collagen which gives rise to a raised scar, but not to the degree observed with keloids. Like keloids, they form most often at the sites of pimples, body piercings, cuts and burns. They often contain nerves and blood vessels. They generally develop after thermal or traumatic injury that involves the deep layers of the dermis and express high levels of TGF-β.
Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions
The present invention relates to findings that reducing the activity of Plasminogen Activator Inhibitor-1 (PAI-1) suppresses an excessive deposition of collagen which is known as a cause for the formation of abnormal scars. These abnormal scars include but are not limited to keloids, adhesions, hypertrophic scars, skin disfiguring conditions, fibrosis, fibrocystic conditions, contractures, and scleroderma, all of which are associated with or caused by an excessive deposit of collagen in a wound healing process. Accordingly, aspects of the present invention are directed to the reduction of PAI-1 activity to decrease an excessive accumulation of collagen, prevent the formation of an abnormal scar, and / or treat abnormal scars that result from an excessive accumulation of collagen. The PAI-1 activity can be reduced by PAI-1 inhibitors which include but are not limited to PAI-1 neutralizing antibodies, diketopiperazine based compounds, tetramic acid based compounds, hydroxyquinolinone based compounds, Enalapril, Eprosartan, Troglitazone, Vitamin C, Vitamin E, Mifepristone (RU486), and Spironolactone to name a few. Another aspect of the present invention is directed to methods of measuring PAI-1 activity in a wound healing process and determining the propensity of the formation of an abnormal scar.
Owner:CHILDRENS HOSPITAL OF LOS ANGELES +1
Application of exosome derived from human mesenchymal stem cells to resistance to tissue fibrosis and scar forming
InactiveCN105477016AAvoid cancer riskInhibition formationAerosol deliveryDigestive systemCardiac fibrosisTissue fibrosis
The invention belongs to the technical field of molecular biology and relates to application of an exosome derived from human mesenchymal stem cells to preparation of medicines for antagonizing scars or tissue and organ fibrosis. According to the application, the high-purity and high-bioactivity exosome is obtained by subjecting healthy human umbilical cords to primary in-vitro culture, collecting liquid supernatant after amplification, performing low-temperature ultracentrifugation, purifying and the like; the exosome is used individually or added into medicines, health care products and cosmetics according to a proportion to be developed into a product with a bioactivity function, thereby being capable of regulating organism cell signal transduction effectively, inhibiting fibrocyte differentiation and then antagonizing the tissue and organ fibrosis and scar forming. Through experimental verification, the exosome can play a remarkable role in repairing promotion in hypertrophic scar after skin injury, particularly pathological fibrosis proliferation such as scar contracture of the joint parts, hepatic fibrosis and cardiac fibrosis, and is high in safety, little in toxicity and convenient to storage and transport, thereby being wide in application prospect.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Treatment of abnormal or excessive scars
InactiveUS20110130710A1Avoid communicationReduce junctionOrganic active ingredientsSenses disorderMedicineAtrophic scarring
Owner:BECKER DAVID LAWRENCE +2
Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
ActiveUS20050032910A1Minimizing and preventing excessive scarringInhibition formationBiocideOrganic active ingredientsKeloidMedicine
Owner:NORTHWESTERN UNIV
Traditional Chinese medicinal composition for treating burns and scalding
InactiveCN102028793AProtect internal organsReduce the incidence of burn complicationsHydroxy compound active ingredientsInanimate material medical ingredientsOysterKeel
The invention discloses a traditional Chinese medicinal composition for treating burns and scalding, which solves the problem that the conventional medicament has long treatment course, low anti-infection capacity, hypertrophic scar, pigementation and itching of the original wound surface after healing and the like. The traditional Chinese medicinal composition for treating the burns and scalding is prepared from the following raw materials in parts by weight: 5 to 20 parts of golden thread, 15 to 50 parts of amur corktree bark, 5 to 20 parts of rhubarb, 15 to 50 parts of gardenia, 15 to 50 parts of baical skullcap root, 5 to 20 parts of liquoric root, 15 to 50 parts of keel, 15 to 50 parts of garden burnet root, 15 to 50 parts of oyster, 15 to 50 parts of weeping forsythia, 15 to 50 parts of honeysuckle flower, 15 to 50 parts of giant knotweed rhizome and 5 to 20 parts of borneol. After being applied to the burned or scalded wound surface, the traditional Chinese medicinal composition for treating the burns and scalding has good antibacterial and bacteriostatic effects, prevents burn infection, alleviates pain of the wound surface, promotes quick healing of the wound surface, prevents hypertrophic scar and pigementation, prevents itching after healing, does not need skin grafting, and has bleeding resistance, short treatment course and no sequela.
Owner:黄文扬
Pharmaceutical composition containing ghrp-6 to prevent and eliminate fibrosis and other pathological deposits in tissues
The present invention is related to the use of secretagogue peptides repeatedly administered as part of a pharmaceutical composition that prevent and eradicate the deposition of pathological fibrotic material in parenchymal tissues of internal organs like the liver, lungs, esophagus, small intestine, kidneys, blood vessels, joints, and other systemic forms of cutaneous fibrosis of any etiopathogenesis. Additionally, these peptides prevent and eradicate deposition of amiloid and hyaline materials in any of their correspondent chemical forms and tissue manifestations in the brain, cerebellum, blood vessels, liver, intestines, kidneys, spleen, pancreas, joints and the skin, among others. By this way, cellular, tissular and organ dysfunctions generated by these depositions are corrected. The peptides of the present invention are infiltrated or topically applied, contributing to prevent and eradicate keloids and hypertrophic scars in the skin, derived as sequelae of burns and other cutaneous trauma.
Owner:CENT DE ING GENETICA & BIOTECNOLOGIA
Method and device for treatment of keloids and hypertrophic scars using focused ultrasound
InactiveUS20110184322A1Increase temperatureEasy to disassembleUltrasound therapyChiropractic devicesMedicineKeloid
A method for treating a scar on a skin surface of a subject is provided. A subject is identified as having a skin surface with scar tissue. In response to identifying the subject as having the scar tissue, a housing comprising at least one acoustic transducer is placed on the skin surface with the scar tissue and the acoustic transducer is activated to apply high intensity focused ultrasound energy to a portion of the scar tissue. Other embodiments are also described.
Owner:SLENDER MEDICAL LTD
Product and method for treating keloid scars, hypertrophic scars and burn scars with contracture
A method of treating keloid scars, hypertrophic scars or burn scars with contracture includes administering low molecular weight hyaluronic acid to the keloid scar, hypertrophic scar or burn scar with contracture.
Owner:COLE RES & DESIGN
Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions
InactiveCN1668312AReduced uPA activityImmunoglobulins against animals/humansMuscular disorderVitamin CFibrosis
Owner:CHILDRENS HOSPITAL OF LOS ANGELES +1
Preventives/remedies for thickened scar, keloid or chronic arthritic diseases
InactiveUS20040096447A1Good control effectImproving effect on progressive proliferation of collagen fibersPeptide/protein ingredientsAntipyreticErythropoietin AntibodyThickened scars
A pharmaceutical preparation for preventing and / or treating hypertrophic scars, keloid or chronic arthritic diseases comprising as an effective component an erythropoietin antagonist. More specifically, there is provided a pharmaceutical preparation for preventing and / or treating hypertrophic scars, keloid or chronic arthritic diseases comprising as an effective component an erythropoietin antagonist such as an anti-erythropoietin antibody, an erythropoietin receptor protein, etc. This pharmaceutical preparation has excellent prophylactic and / or therapeutic effects on collagenous hyperproliferation such as hypertrophic scars, keloid, etc., or chronic arthritic diseases such as rheumatoid arthritis, etc.
Owner:YASUDA YOSHIKO
Pharmaceutical Composition Containing GHRP-6 To Prevent And Eliminate Fibrosis And Other Pathological Deposits In Tissues
The present invention is related to the use of secretagogue peptides repeatedly administered as part of a pharmaceutical composition that prevent and eradicate the deposition of pathological fibrotic material in parenchymal tissues of internal organs like the liver, lungs, esophagus, small intestine, kidneys, blood vessels, joints, and other systemic forms of cutaneous fibrosis of any etiopathogenesis. Additionally, these peptides prevent and eradicate deposition of amiloid and hyaline materials in any of their correspondent chemical forms and tissue manifestations in the brain, cerebellum, blood vessels, liver, intestines, kidneys, spleen, pancreas, joints and the skin, among others. By this way, cellular, tissular and organ dysfunctions generated by these depositions are corrected. The peptides of the present invention are infiltrated or topically applied, contributing to prevent and eradicate keloids and hypertrophic scars in the skin, derived as sequelae of burns and other cutaneous trauma.
Owner:CENT DE ING GENETICA & BIOTECNOLOGIA
Liposome gel preparation and preparation method and application thereof
ActiveCN102697705AImprove poor water solubilityImprove stabilityAerosol deliveryOintment deliveryGel preparationLipid particle
The invention provides a liposome gel preparation for treating hypertrophic scars. The liposome gel preparation comprises liposome, gel material and glycerol, wherein the liposome is encapsulated with paeonol, and the surface of the liposome is bonded with vascular endothelial growth factor (VEGF) antibodies through polyethylene glycol. The invention provides a preparation method and application of the gel preparation at the same time. The gel preparation is encapsulated by using a material such as phospholipid with good physiological compatibility with the human body, so that the problems of poor water solubility and low stability of the paeonol are effectively solved. The VEGF antibodies are used for modifying the surface of the liposome, lipid particles enter the dermis through the epidermis by using the permeation promoting effect of liposome carriers and are directionally bonded with VEGF receptors of the pathological change skin part, and the encapsulated medicament is released at the same time, so that positioned retention of the medicament in the scar hyperplasia part is realized. Compared with other reported scar hyperplasia resistant medicament preparations or treatment schemes, the invention has the advantages that the liposome gel preparation is low in relapse rate, reduces the occurrence rate of the toxic or side effect and can be applied to any scar hyperplasia part of the body.
Owner:GUANGDONG PHARMA UNIV
Treatment of skin disorders
An effective treatment for skin disorders characterized by abnormal skin cell behavior, including a pharmaceutically effective amount of Halofuginone. Skin disorders which can be treated include keloids, hypertrophic scars, psoriasis, acne, seborrhea and alopecia. Halofuginone can reduce or eliminate clinical symptoms of these disorders, as well as substantially prevent the formation of keloids and hypertrophic scars.
Owner:HADASIT MEDICAL RES SERVICES & DEVMENT
Microneedle patch for scar treatment and preparation method thereof
InactiveCN112999297AHave mechanical strengthEasy to useOrganic active ingredientsMicroneedlesPolyvinyl alcoholPolyethylene glycol
The invention provides a microneedle patch for scar treatment and a preparation method thereof, the microneedle patch comprises a substrate and a needle body arranged on the surface of the substrate, the needle body comprises an anti-scar active component and a matrix material, the anti-scar active component comprises onion extract, cannabis sativa leaf extract, allantoin and heparin sodium in a mass ratio of 1: (0-1): (0-0.5): (0-0.02); the anti-scar active component mainly comprises an onion extract, the substrate also comprises a matrix material, and the matrix material comprises but not limited to hyaluronic acid, sodium hyaluronate, polyvinyl alcohol, polyvinylpyrrolidone, polyethylene glycol, sodium carboxymethyl cellulose, hydroxypropyl-beta-cyclodextrin, sodium alginate, polylactic acid, chitosan and glucan; the microneedle patch for scar treatment has certain mechanical strength, is convenient to use and good in stability, can realize minimally invasive painless effect when acting on skin, and provides a new and effective method for treatment of hypertrophic scars at any part of a body.
Owner:上海行渝生物科技有限公司
siRNA molecular composition and application thereof in treatment on pathological scars
InactiveCN104174032APromote apoptosisGood treatment effectGenetic material ingredientsDermatological disorderMolecular compositionMedicine
The invention relates to a siRNA molecular composition and application thereof in treatment on hypertrophic scars and keloids. The siRNA molecular composition contains siRNA molecules with the sequence of 5'-CCCAAGGGCUACCAUGCCAACUUCU-3' and siRNA molecules with the sequence of 5'-GGUCUGGUGCCUGGUCUGAUGAUGU-3'. The siRNA molecular composition is proved to be capable of promoting in-vitro fibroblast apoptosis of the hypertrophic scars and keloids and have a good treatment effect on the hypertrophic scars in an animal model.
Owner:SHANGHAI NINTH PEOPLES HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Biological beautifying preparation containing autologous stroma cells
ActiveCN104173252AImprove wrinklesAcne scar repairCosmetic preparationsToilet preparationsBlood plasmaAcne scarring
The invention provides a method for preparing a biological beautifying preparation containing autologous stroma cells. The method comprises the following steps: acquiring autologous plasma from autologous peripheral blood and culturing to acquire autologous stroma cells; and adding the autologous stroma cells into the autologous plasma to prepare the biological beautifying preparation. The invention simultaneously provides the biological beautifying preparation prepared from the autologous stroma cells and the autologous plasma, which is added with growth factors and anti-oxidation factors, and is capable of removing skin wrinkles, repairing acne scarring, repairing and improving burns, trauma and hypertrophic scars, resisting senescence and the like.
Owner:蔡贤芬
Recombinant adenoviral vectors and their utility in the treatment of various types of fibrosis: hepatic, renal, pulmonary, as well as hypertrophic scars
<heading lvl="1">SUMMARY OF THE INVENTION < / heading> The use of gene therapy for the treatment of different kinds of fibrosis in human beings is disclosed. The purpose is the use of "therapeutic2 genes specifically directed to target organs to revert and / or prevent the development of the fibrosis process. The potential application of gene therapy to patients with fibrosis and / or cirrhosis will depend to a large extent on the successful delivery of genes which encode for therapeutic proteins to livers with severe fibrosis and that these genes which encode for proteins human MMP-8 active and latent, MMP-1, MMP-2, MMP-9 and MMP-13; human uPA wild type and / or modified (or its truncated version), the truncated receptor for TGF-beta type II and Smad-7 can be directed by adenovirus and / or other recombinant vectors that cannot transduce (infect) others organs. The recombinant adenoviruses (AdR) are vectors highly efficient for the transduction of therapeutic genes to diverse target cells. We have proved that they can carry genes to cirrhotic livers. The delivery of therapeutic genes through such adenoviral vectors and other recombinant vectors could also be performed using cationic and anionic liposomes (DOTMA). Therefore, we propose the use of this patent to be applied in the same manner to: Renal fibrosis Pulmonary fibrosis Hypertrophic and keloid scars (skin fibrosis), and Other kinds of fibrosis.
Owner:TGT LAB DE C V
Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
ActiveUS7767717B2Preventing and minimizingInhibition formationBiocideOrganic active ingredientsMedicineKeloid
The present invention provides a method for treating or preventing excessive scarring, including keloid and hypertrophic scars, by administering 4-hydroxy tamoxifen to a patient with excessive scarring or a wound at risk for developing excessive scarring.
Owner:NORTHWESTERN UNIV
Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (CTGF)
This invention provides methods of preventing formation of, or treating, fibrotic lesions, including skin scars such as keloids and hypertrophic scars which comprise administering to the subject by one or more injection a compound which comprises a modified oligonucleotide, such as a modified antisense oligonucleotide, siRNA, or oligodeoxyribonucleotide, which inhibits expression of protein involved in fibrosis. Dosing of the antisense using an intradermal threading technique is also described.
Owner:PFIZER INC
Microacupuncture needle paster for improving skin hyperplastic scars and preparation method of microacupuncture needle paster
ActiveCN110935097APromote growthPrevent drynessCosmetic preparationsToilet preparationsSilicone GelsPolymer science
The invention discloses a microacupuncture needle paster for improving skin hyperplastic scars. The microacupuncture needle paster comprises a microacupuncture needle array loaded with active constitutents, a fixed connecting layer and a hydrogel layer, wherein the microacupuncture needle array is located on the first surface of the fixed connecting layer; the hydrogel layer is arranged on the second surface of the fixed connecting layer; the fixed connecting layer is located between the microacupuncture needle array and the hydrogel layer; a plurality of infiltration channels are formed in the fixed connecting layer, penetrate through the fixed connecting layer, and communicate with the microacupuncture needle array and the hydrogel layer; the fixed connecting layer comprises a silicone gel matrix and strengthening fibers; the strengthening fibers are connected with the silicone gel matrix and are used for supporting the silicone gel matrix; and the infiltration channels are formed inthe silicone gel matrix. According to the microacupuncture needle paster for improving the skin hyperplastic scars disclosed by the invention, the wound ulceration period can be accelerated and improved, the risk of forming hyperplastic scars during wound healing can be reduced, and local state blemish in skin after the hyperplastic scars are formed can also be improved.
Owner:广州新济薇娜生物科技有限公司
Use of Bcl Inhibitors for the Treatment of Scarring Caused By Cutaneous Wounds, Burns and Abrasions
The present invention relates to use of Bcl inhibitors for the prevention of fibroproliferation resulting in the growth of visible or disfiguring scar tissue on human skin, including without limitation keloids and hypertrophic scars. In particular, the present invention relates to the new use of small molecule inhibitors of the Bcl-2 / Bcl-XL family of anti-apoptotic proteins for the treatment of cutaneous wounds, burns and abrasions during the healing phase.
Owner:MCCAFFREY TIM +2
ITGB4BP and derivates thereof used for preventing and/or treating hypertrophic scar and fibrosis lesion
The invention relates to the new applications of integrin beta 4 binding protein (ITGB4BP) and derivates thereof, or gene recombinant expression vector expressing the ITGB4BP or derivates thereof in preventing and / or treating hypertrophic scar or fibrosis lesion; wherein, the amino acid sequence of the ITGB4GB is SEQ ID NO 1; the derivates of the ITGB4BP are protein derivates retaining the combining site and the functional site of the ITGB4BP (SEQ ID NO 1). The application is realized by applying the ITGB4BP or derivates thereof, or gene recombinant expression vector expressing the ITGB4BP orderivates thereof, or the drug combination or the kit of the invention on subjects with an effective dose in treatment. The drug combination or the kit contains the ITGB4BP or derivates thereof, or gene recombinant expression vector expressing the ITGB4BP or derivates thereof and an officinal excipient or vectors and the like with an effective dose in treatment. Preferably, the subjects are humanbeings or animals.
Owner:SOUTHWEST HOSPITAL OF CHONGQING
Preparation method and application of capsaicin-collagen sponge
ActiveCN104490760AImproves transdermal penetrationAvoid first pass effectOrganic active ingredientsPharmaceutical delivery mechanismFreeze-dryingEthylic acid
The invention relates to the technical field of external medicines for hypertrophic scars, and particularly relates to a preparation method and an application of capsaicin-collagen sponge. The preparation method comprises the following steps: 1 preparing collagen powder from tendo calcaneus; 2 extracting the collagen powder with pepsin, so as to obtain an extract liquid; 3 centrifugally collecting supernate; 4 separating out collagen by adding sodium hydroxide, and washing, so as to prepare high-purity collagen; 5 redissolving the collagen with ethylic acid; and 6 evenly mixing the collagen liquid, glycerinum and capsaicin, and then carrying out freeze-drying, so as to obtain the capsaicin-collagen sponge. The capsaicin-collagen sponge prepared by the method is applied to tissue trauma repair and inhibition of the hypertrophic scars in the tissue trauma repair process, and has the advantage of good percutaneous permeability; the drug liver first-pass effect can be avoided; and the thrill to the skin can be reduced.
Owner:GUANGDONG MEDICAL UNIV
Breathable itching-relieving antisepsis scar treating paster and preparation method thereof
ActiveCN103550254AHydroxy compound active ingredientsInorganic active ingredientsMedicineBULK ACTIVE INGREDIENT
The invention belongs to the technical field of treating skin scars, and particularly relates to a breathable itching-relieving antisepsis scar treating paster and a preparation method thereof. The technical problem to be solved is to provide a new choice for treating a hypertrophic scar. According to the technical scheme, the breathable itching-relieving antisepsis scar treating paster is prepared from the following active ingredients in percentage by weight: 97.9% of silicone, 1% of mint, 1% of borneol, 0.05% of heparin sodium, and 0.05% of nanosilver. The invention further provides a preparation method for the breathable itching-relieving antisepsis scar treating paster. The treating paster provides a new choice for treating the scar.
Owner:THE FIRST AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIVERSITY OF PLA
Hydrogel compositions, methods for preparing the same and uses thereof
InactiveCN107249574ASuppresses or even eliminates irritantsImprove cooling effectHydroxy compound active ingredientsAntipyreticEtiologyCore shell nanoparticles
Disclosed are hydrogel composition, method for preparing the same and use thereof. The hydrogel composition comprises a guar gum derivative which is crosslinked, a mint-based component, water, and optionally, an amphiphilic core-shell nanoparticle having a hydrophobic core and a hydrophilic shell, wherein the amount of the mint-based component is in the range of 1-6 wt%and the amount of the water is in the range of 65-95 wt%, based on the total weight of the hydrogel composition. The hydrogel composition is safe and can provide symptomatic relief for patients with symptoms such as severe and intractable pruritus associated with hypertrophic scars. The symptomatic relief effect of the hydrogel composition is reproducible, and is independent of the etiology of the burn trauma, extent of the scarring and duration of the scar formation, while tachyphylaxis is not observed. Also disclosed is a medical device comprising the hydrogel composition.
Owner:CHONGQING MJ MEDICAL DEVICES
Hydrogel adapted for treatment of acute dermal wounds
The present invention provides compositions and methods useful in the treatment of wounds, particularly in reducing or preventing scar formation, particularly hypertrophic scar or keloid formation. The invention thus further provides methods of treatment, including methods useful in hypertrophic scar or keloid revision as well as prophylactic, scar inhibiting methods.
Owner:HALSCION
Methods for treating and limiting fibrotic disorders and keloids
The present invention provides methods for treating and / or limiting fibrotic disorders and / or treating or limiting scars selected from the group consisting of keloids and hypertrophic scars comprising administering to an individual in need thereof an amount effective to treat and / or limit scars selected from the group consisting of keloids and hypertrophic scars of a polypeptide comprising an HSP20- related polypeptide.
Owner:亚利桑那州董事会代表的亚利桑那州大学
De novo synthesis of glucocorticoids in the epidermis and its uses and applications
Owner:NEW YORK UNIV
Mixture of betamethasone and tranilast with a transdermal gel for scar treatment
ActiveUS9173940B1Suppressing collagen synthesisInhibit expressionOrganic active ingredientsPeptide/protein ingredientsBetamethasone valerateOleic Acid Triglyceride
Owner:PROFESSIONAL COMPOUNDING CENTS OF AMERICA PCCA
Prescription and preparation method for tranilast gel and ointment
InactiveCN104784101AIncrease drug concentrationFully absorbedOrganic active ingredientsAerosol deliveryTherapeutic effectAugmented Ointment
Belonging to the field of medical technologies, the invention relates to a prescription and preparation method for topical gel and ointment dosage forms containing tranilast component, and therapeutic effects of the dosage forms in keloid and hypertrophic scar fields. The topical gel and ointment contain tranilast, a cosolvent, a substrate, a humectant, a penetration enhancer, a preservative, a pH regulator, purified water and other ingredients. The preparation method includes the steps of: 1. taking a prescribed amount of the substrate, adding a proper amount of purified water, performing full swelling at 20-80DEG C, adjusting the pH to less than 5, adding a prescribed amount of humectant, and conducting heat preservation to obtain A; 2. taking a prescribed amount of tranilast, the cosolvent, the preservative, and a proper amount of purified water, carrying out heating dissolving at 20-80DEG C, and performing heat preservation to obtain B; and 3. Pouring B into A, conducting heat preservation and swelling, and stirring the mixture evenly, thus obtaining the products. The tranilast gel and ointment provided by the invention have the pharmacological activity of treating hypertrophic scars and keloids.
Owner:药大制药有限公司
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com